Tag Archives: Augmentin

Alzheimer’s Therapy: Gene Therapy

Overview. Gene therapy for Alzheimer’s disease is a long way from being practicable, but some prototypical approaches are being explored. In April 2001, Ceregene, a subsidiary of Cell Genesys, began a Phase I trial for its nerve growth factor (nerve growth factor) gene delivery involving eight patients with early Alzheimer’s disease. Another promising approach pioneered… Read More »

When to Introduce Antipsychotics

Question. When do you feel antipsychotics should be used to treat anxiety? My patient is very distressed, cannot concentrate and has a hard time with rational thought. He suggested this as a possible option, but what do you think? Answer. Unless the anxiety is really secondary to a psychotic process, I would argue that the… Read More »

Minor Depression: Triple Reuptake Inhibitors

A novel mechanism for the treatment of depression that has attracted much attention is triple reuptake inhibition. Given their additional mechanism of action on dopamine, the triple reuptake inhibitors pose a potential threat to the clinical use and commercial fortunes of selective serotonin reuptake inhibitors and serotonin/norepinephrine reuptake inhibitors. Agents of this type are being… Read More »

Schizophrenia: Other Pharmacological Treatments

Because antipsychotic medications often fail to resolve the full range of schizophrenic psychopathology and other common symptoms (e.g., anxiety, depression, mood instability, motor unrest), adjunctive treatments are commonly tried. Adjunctive pharmacological treatments in patients with schizophrenia have been the subject of numerous reviews (). In addition, some psychotropic medications other than antipsychotics have been used… Read More »

TR-PTSD: Implications for Clinicians

TR-PTSD: Treatment Resistant Posttraumatic Stress Disorder While SSRIs and cognitive behavioral therapy have been deemed the prime treatment for PTSD (posttraumatic stress disorder), many do not respond. There are many different factors contributing to treatment-resistance and it varies between individuals. As such, there is limited evidence-based research on the obvious next step for treatment of… Read More »

Adequate and Poor Response to Pharmacotherapy

Switching Medication And Augmentation Strategies In most studies, response is commonly defined as a >50% reduction on the commonly used standard scales. This definition is also arbitrary, because that cannot be applied for all disorders. Assessment of changes on disease-specific rating scales and measures of global illness severity and improvement, social, occupational, and academic functioning,… Read More »

Combination Treatments

Although the antiobsessional efficacy of the serotonin selective reuptake inhibitors and clomipramine is now well established, a substantial proportion of patients, around 30-40%, respond poorly or do not respond at all to treatment. The problem of treatment resistance and its management is complicated by our lack of understanding of the underlying pathophysiology of obsessive-compulsive disorder.… Read More »

Pharmacotherapy in the Treatment of Obesity

Until the 1990s, pharmacotherapy played a relatively minor role in the treatment of obesity. Available drugs were approved only for very short-term use. Difficulties in performing longer term studies, concerns regarding the safety and abuse of drugs, and consistent findings showing rapid weight regain following drug discontinuation contributed to the fact that no new obesity… Read More »

Treatments for OCD: Choosing Among Drugs

Choosing Among Drugs The choice of an initial drug is between one of the available SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram) or the use of the TCA clomipramine. The efficacy of all these agents is very similar, and the choice is usually determined by drug tolerability, safety, side effects, cost, and the patient’s previous drug… Read More »